Interpace Biosciences Inc
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an … Read more
Interpace Biosciences Inc (IDXG) - Net Assets
Latest net assets as of September 2025: $-298.00K USD
Based on the latest financial reports, Interpace Biosciences Inc (IDXG) has net assets worth $-298.00K USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.04 Million) and total liabilities ($12.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-298.00K |
| % of Total Assets | -2.48% |
| Annual Growth Rate | N/A |
| 5-Year Change | -112.7% |
| 10-Year Change | -117.0% |
| Growth Volatility | 359.11 |
Interpace Biosciences Inc - Net Assets Trend (2000–2024)
This chart illustrates how Interpace Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Interpace Biosciences Inc (2000–2024)
The table below shows the annual net assets of Interpace Biosciences Inc from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-2.22 Million | +96.41% |
| 2023-12-31 | $-61.67 Million | +2.22% |
| 2022-12-31 | $-63.07 Million | -1631.62% |
| 2021-12-31 | $4.12 Million | -76.41% |
| 2020-12-31 | $17.45 Million | -19.55% |
| 2019-12-31 | $21.69 Million | -34.14% |
| 2018-12-31 | $32.94 Million | -17.38% |
| 2017-12-31 | $39.87 Million | +510.46% |
| 2016-12-31 | $6.53 Million | -49.91% |
| 2015-12-31 | $13.04 Million | -35.21% |
| 2014-12-31 | $20.12 Million | -38.05% |
| 2013-12-31 | $32.48 Million | -8.84% |
| 2012-12-31 | $35.63 Million | -40.14% |
| 2011-12-31 | $59.52 Million | -14.37% |
| 2010-12-31 | $69.51 Million | -7.18% |
| 2009-12-31 | $74.89 Million | -30.08% |
| 2008-12-31 | $107.11 Million | -23.60% |
| 2007-12-31 | $140.19 Million | -6.04% |
| 2006-12-31 | $149.20 Million | +10.02% |
| 2005-12-31 | $135.61 Million | -18.02% |
| 2004-12-31 | $165.43 Million | +19.45% |
| 2003-12-31 | $138.49 Million | +12.40% |
| 2002-12-31 | $123.21 Million | -18.37% |
| 2001-12-31 | $150.94 Million | +9.29% |
| 2000-12-31 | $138.11 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Interpace Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 665.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $233.16 Million | % |
| Total Equity | $-2.22 Million | 100.00% |
Interpace Biosciences Inc Competitors by Market Cap
The table below lists competitors of Interpace Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nakoda Group of Industries Limited
NSE:NGIL
|
$1.85 Million |
|
Kanani Industries Limited
NSE:KANANIIND
|
$1.85 Million |
|
CopperEx Resources Corporation
V:CUEX
|
$1.85 Million |
|
Highway 50 Gold Corp
PINK:HGGCF
|
$1.85 Million |
|
Tactical Resources Corp.
PINK:USREF
|
$1.85 Million |
|
Merino & Co. Ltd
AU:MNC
|
$1.85 Million |
|
Mint Corp
V:MIT
|
$1.85 Million |
|
HERSHEY
MU:HSY
|
$1.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Interpace Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -61,672,000 to -2,217,000, a change of 59,455,000.
- Net income of 6,702,000 contributed positively to equity growth.
- Other factors increased equity by 52,753,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $6.70 Million | +302.3% |
| Other Changes | $52.75 Million | +2379.48% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Interpace Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $2.14 | $0.90 | x |
| 2014-12-31 | $1.31 | $0.90 | x |
| 2015-12-31 | $0.74 | $0.90 | x |
| 2016-12-31 | $3.00 | $0.90 | x |
| 2017-12-31 | $14.32 | $0.90 | x |
| 2018-12-31 | $11.48 | $0.90 | x |
| 2019-12-31 | $-11.42 | $0.90 | x |
| 2020-12-31 | $-7.17 | $0.90 | x |
| 2021-12-31 | $0.98 | $0.90 | x |
| 2022-12-31 | $-14.68 | $0.90 | x |
| 2023-12-31 | $-14.17 | $0.90 | x |
| 2024-12-31 | $-0.50 | $0.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Interpace Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.28%
- • Asset Turnover: 3.17x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-40.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 19.57% | 6.48% | 1.54x | 1.96x | $13.22 Million |
| 2001 | 4.21% | 0.91% | 2.30x | 2.01x | $-8.74 Million |
| 2003 | 8.85% | 3.56% | 1.57x | 1.59x | $-1.59 Million |
| 2004 | 12.77% | 5.80% | 1.62x | 1.36x | $4.59 Million |
| 2006 | 7.92% | 4.94% | 1.19x | 1.35x | $-3.11 Million |
| 2011 | -20.02% | -7.57% | 1.39x | 1.90x | $-17.87 Million |
| 2012 | -71.64% | -20.12% | 1.62x | 2.20x | $-29.09 Million |
| 2013 | -14.06% | -3.03% | 2.18x | 2.13x | $-7.81 Million |
| 2014 | -79.88% | -13.40% | 1.03x | 5.76x | $-18.09 Million |
| 2015 | -87.10% | -120.40% | 0.14x | 5.19x | $-12.66 Million |
| 2016 | -127.58% | -63.68% | 0.31x | 6.40x | $-8.99 Million |
| 2017 | -30.64% | -76.84% | 0.30x | 1.34x | $-16.20 Million |
| 2018 | -37.01% | -55.67% | 0.45x | 1.47x | $-15.48 Million |
| 2019 | 0.00% | -110.40% | 0.47x | 0.00x | $-26.29 Million |
| 2020 | 0.00% | -81.64% | 0.71x | 0.00x | $-23.54 Million |
| 2021 | -362.87% | -36.17% | 1.08x | 9.33x | $-15.35 Million |
| 2022 | 0.00% | -68.97% | 1.99x | 0.00x | $-15.65 Million |
| 2023 | 0.00% | 4.88% | 3.07x | 0.00x | $8.12 Million |
| 2024 | 0.00% | 14.28% | 3.17x | 0.00x | $6.92 Million |
Industry Comparison
This section compares Interpace Biosciences Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $867,957,363
- Average return on equity (ROE) among peers: -141.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Interpace Biosciences Inc (IDXG) | $-298.00K | 19.57% | N/A | $1.85 Million |
| Agilent Technologies Inc (A) | $4.57 Billion | 6.91% | 0.87x | $31.45 Billion |
| Amer Bio Medica (ABMC) | $-944.00K | 0.00% | 0.00x | $3.55K |
| ADCNF (ADCNF) | $612.34 Million | 111.18% | 6.93x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.64 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $4.37 Million | -93.77% | 0.93x | $36.19K |
| Avricore Health Inc (AVCRF) | $3.35 Million | -65.62% | 0.06x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $4.67 Million | -153.12% | 0.85x | $664.47K |
| Biodesix Inc (BDSX) | $4.58 Million | -1138.56% | 20.64x | $48.86 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |